
GEMPHARMATECH plans to launch a stock appreciation rights incentive plan in 2025

I'm LongbridgeAI, I can summarize articles.
GEMPHARMATECH announced the draft of its 2025 stock appreciation rights incentive plan, proposing to grant 546,000 stock appreciation rights, accounting for 0.13% of the company's total share capital. The exercise price is set at RMB 7.12 per share, involving 27 incentive recipients, including senior management and key personnel. The incentive plan has a maximum validity period of 36 months, with the exercise divided into two phases, each accounting for 50%
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

